Cholangiocarcinoma

At the 10th Annual Cholangiocarcinoma Foundation Conference, Rachna Shroff, MD, MS, Chief, Gastrointestinal Medical Oncology, and Director, Clinical Trials Office, University of Arizona Cancer Center, Tucson, and Madhulika Eluri, MD, Hematology/Oncology Fellow, The University of Texas MD Anderson Cancer Center, Houston, debated whether chemotherapy remains the backbone for cholangiocarcinoma (CCA) treatment or if it is time to move away from this therapeutic strategy. Read More ›

At the 10th Annual Cholangiocarcinoma Foundation Conference, Michael E. Lidsky, MD, Assistant Professor, Surgical Oncology, Duke University School of Medicine, Durham, NC, presented his research on a novel model to investigate FGFR signaling and how this information may lead to a new treatment strategy for FGFR2 fusion–positive cholangiocarcinoma (CCA). For patients with advanced CCA, surgery is often not an option, and patients are left with systemic therapy as the only treatment option. Read More ›

Over the years, the therapeutic landscape for cholangiocarcinoma (CCA) has expanded beyond chemotherapy to include immunotherapy and targeted therapies as part of an individualized approach to treatment. At the 10th Annual Cholangiocarcinoma Foundation Conference, Tim F. Greten, MD, Deputy Chief, Thoracic and GI Malignancies Branch; Head, Gastrointestinal Malignancy Section; and Co-Director, National Cancer Institute Center for Cancer Research Liver Cancer Program, Bethesda, MD, discussed novel targets for future CCA treatments coming from translational research studies. Read More ›

Cholangiocarcinoma (CCA), a rare and aggressive form of cancer, has seen a steady increase in incidence in the United States, with a predominant increase in intrahepatic CCA, from 2001 to 2017, according to a recent epidemiological study. Read More ›

At the 4th Annual Cholangiocarcinoma Summit, held on October 13-15, 2022, experts in the field of gastroenterology, interventional radiology, nursing, and surgery discussed the importance of using a multidisciplinary approach to supportive care and the management of complications in patients with biliary tract cancers (BTCs). Read More ›

On October 21, 2022, the FDA approved tremelimumab (Imjudo; AstraZeneca), a CTLA-4 monoclonal antibody, in combination with durvalumab (Imfinzi; AstraZeneca), a PD-L1 inhibitor, for the treatment of adults with unresectable hepatocellular carcinoma (HCC). Read More ›

A comparison of clinical trials found progression-free survival with futibatinib to be significantly greater compared with chemotherapy and that trials favor futibatinib over pemigatinib for all efficacy parameters. Read More ›

Real-world evidence supports a role for liquid biopsy in identifying molecular alterations and offering personalized treatment options, with IDH1 identified in a patient with cholangiocarcinoma. Read More ›

Preliminary quality-of-life data suggest a potentially positive impact of L-folinic acid plus oxaliplatin plus 5-fluorouracil when used in conjunction with active symptom control. Read More ›

The NALIRICC study did not meet overall survival or progression-free survival end points, with nanoliposomal irinotecan plus 5-fluorouracil falling short in patients with metastatic biliary tract cancer. Read More ›